Skip To Main Content

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques
Underneath the skin

Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

Advancing the treatment: Meeting the challenge of uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Advancing Treatment for Uncontrolled AD and PN: New Approaches

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.

Lipid management in patients with diabetes mellitus

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Et si un historique de fractures osseuses et de douleurs sous-tendait une maladie rare ?

Et si un historique de fractures osseuses et de douleurs sous-tendait une maladie rare ?

Défi clinique : Une jeune de 18 ans avec des douleurs à la hanche et un boitement

Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

Switching from other basal insulins to Toujeo<sup>®</sup> (Insulin Glargine)

Switching from other basal insulins to Toujeo (Insulin Glargine)

Autoimmune Type 1 Diabetes

Autoimmune Type 1 Diabetes

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.1-4 

The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2

The RESTORE-G Real World Evidence Study

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

The Deliver-G study

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

The observational ORION study

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.